AR-14034 SR implant

Phase 2

Alcon Research (ALC)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

ALCPhase 2$31.9B

AR-14034 SR implant Phase 2 Est. Readout (NOVA-1)

AR-14034 SR implant• Neovascular Age-related Macular Degeneration (nAMD)139

Apr 2027~Estimated

CT.gov

00%

Competitive Landscape

2 competitors in Neovascular Age-related Macular Degeneration (nAMD)

RHHBYVabysmo

RHHBYranibizumab injection

Approved

View Full Landscape

Drug Information

Target Indication

Neovascular Age-related Macular Degeneration (nAMD)

Clinical Trial

NCT05769153

Last updated: 10/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•Europe•NASDAQ

Related Pipeline

Dorzolamide+timolol ophthalmic solutionPhase 3

Glaucoma

AZOPT (brinzolamide)Phase 3

Glaucoma

Artificial tearsPhase 3

Dry Eye Disease

Timolol Gel-forming Solution (TGFS)Phase 3

Glaucoma

Latanoprost/TimololPhase 3

Glaucoma, Open-Angle

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts